TriangleNCT00309946 · OUTCOME
Changes in Laboratory Correlates
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Baseline, days 15 and 29 of course 1, and then every 28 days
What was measured
Examined using paired t-test or Wilcoxon signed-ranks test.
Analysis population: This outcome was not measured/assessed for any of the study subjects.
Groups in this outcome
Treatment (Enzyme Inhibitor Therapy)
Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.
| Group | Source count |
|---|---|
| Treatment (Enzyme Inhibitor Therapy) | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- Examined using paired t-test or Wilcoxon signed-ranks test.
- groups
- description
- Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.
- id
- OG000
- title
- Treatment (Enzyme Inhibitor Therapy)
- population Description
- This outcome was not measured/assessed for any of the study subjects.
- reporting Status
- POSTED
- time Frame
- Baseline, days 15 and 29 of course 1, and then every 28 days
- title
- Changes in Laboratory Correlates
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice